15 Independence Boulevard
Suite #410
Warren, NJ 07059
United States
877-838-6436
https://tevogen.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo:
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. | Co-Founder, CEO & Chairman | 466,05k | N/A | 1965 |
Mr. Kirti Desai | Chief Financial Officer | 279,07k | N/A | 1957 |
Dr. Neal Flomenberg M.D. | Chief Scientific Officer and Global R&D Lead | 325,58k | N/A | 1954 |
Mr. Sadiq Khan | Chief Commercial Officer | N/A | N/A | 1962 |
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
El ISS Governance QualityScore de Tevogen Bio Holdings Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.